Trump Denies Reports of Plans to Dismiss FDA Commissioner

2026-05-09

The BareStory

President Donald Trump stated on Friday that he is unaware of any plans to fire Food and Drug Administration Commissioner Marty Makary. Trump's comments followed reports citing unnamed administration officials who claimed the White House had recently authorized a plan for Makary's removal.

Reports of Makary's potential dismissal surfaced alongside allegations of internal disagreements over product approvals and staffing. According to unnamed sources, Trump pressured Makary to authorize fruit-flavored nicotine vapes after meeting with an industry representative. The commissioner reportedly hesitated before approving the products on Tuesday. Additionally, a senior health official claimed Makary has clashed with department leadership over personnel decisions.

Confirmed to the post in March 2025, Makary has faced public criticism from both industry leaders and political groups. SBA Pro-Life America President Marjorie Dannenfelser called for his firing, accusing him of delaying a safety review for the abortion medication mifepristone. John Crowley, head of the Biotechnology Innovation Organization, has also criticized Makary's implementation of personnel cuts at the health agency.

Despite the criticism, the commissioner maintains backing from advocates associated with Health and Human Services Secretary Robert F. Kennedy Jr. These supporters, including several prominent health bloggers and podcasters, allege that calls for Makary’s removal are driven by corporate and pharmaceutical interests. They argue his dismissal would negatively impact independent scientific scrutiny at the FDA.

Left Perspective

Shield Against Corporate Capture
Defend Essential Civil Liberties
Preserve Independent Scientific Scrutiny

Right Perspective

Enforce Unified Executive Authority
Safeguard Foundational Social Order
Maintain Essential Systemic Stability

Left Perspective

• Shield Against Corporate Capture Government accountability relies on strong institutional firewalls between public health and private profit. The Left views Trump’s successful pressure on Makary to approve fruit-flavored vapes immediately following an industry meeting as a dangerous subversion of regulatory integrity. Protecting vulnerable demographics from corporate exploitation requires an FDA that cannot be strong-armed by direct, closed-door lobbying.

• Defend Essential Civil Liberties Safeguarding social progress necessitates keeping ideological agendas out of scientific and medical reviews. SBA Pro-Life America’s demand to fire Makary over his handling of the abortion medication mifepristone is interpreted as a direct assault on reproductive rights. This camp prioritizes insulating foundational healthcare access from aggressive partisan pressure campaigns that seek to roll back established civil liberties.

• Preserve Independent Scientific Scrutiny Challenging the institutional status quo means protecting leaders who resist entrenched pharmaceutical and corporate interests. Embracing the arguments of advocates tied to Robert F. Kennedy Jr., this perspective fears that ousting Makary would validate suspicions that the agency is effectively controlled by industry giants. Removing a commissioner for hesitating on political directives establishes a precedent that permanently subordinates objective science to executive whims.

Right Perspective

• Enforce Unified Executive Authority Institutional continuity requires a cohesive chain of command where appointed officials swiftly execute the elected president's mandate. The Right interprets Makary’s hesitation on vape approvals and his reported clashes with department leadership over personnel as destabilizing insubordination. A functional government relies on agency heads aligning with the White House's agenda rather than operating as autonomous, disruptive factions.

• Safeguard Foundational Social Order Preserving established societal systems requires regulators who respect and prioritize traditional civic values. Marjorie Dannenfelser’s criticism regarding the delayed safety review of mifepristone reflects a demand for strict accountability on matters of life and family. This camp views the FDA's vast regulatory apparatus as an entity that must be actively managed to uphold, rather than undermine, the administration's mandate for social order.

• Maintain Essential Systemic Stability Preserving established systems means ensuring agencies function reliably without capricious internal overhauls. John Crowley’s complaints regarding Makary’s personnel cuts highlight a breakdown in institutional efficiency and regulatory predictability. For traditionalists, internal administrative friction threatens the stable operations of the biotechnology sector, demonstrating that Makary's leadership is undermining the fundamental continuity of the health apparatus.

How it may affect me

As a U.S. reader:

• In the short term, consumers will have market access to fruit-flavored nicotine vapes, which were recently authorized by the FDA following meetings between the executive branch and industry representatives.

• Long-term access to the abortion medication mifepristone could be impacted, as the FDA faces sustained political pressure to adjust its safety review timeline to align with traditional civic values.

• Personnel cuts and internal leadership clashes at the FDA may cause short-term disruptions in regulatory predictability, potentially affecting the biotechnology sector and the efficiency of new medical treatment approvals.

• Over the long term, the precedent of overriding the FDA commissioner's hesitations means consumer health protections and drug approvals may increasingly reflect executive directives and corporate lobbying rather than independent scientific scrutiny.

Trump Denies Reports of Plans to Dismiss FDA Commissioner

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at